News Releases | LumiraDx

Year

28 Sep '21

LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.

LumiraDx’s common shares will commence trading on September 29, 2021 on Nasdaq under the ticker symbol “LMDX” The Merger values LumiraDx at $3.0 billion (excluding the amounts raised by CAHC in its initial public offering) BOSTON & LONDON --(BUSINESS WIRE)--Sep.

21 Sep '21

Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19

From the Bill and Melinda Gates Foundation: The world's response to COVID-19 has been far faster than any disease in history. To get the virus under control, the world needs access to new tools, such as fast, affordable, and accurate diagnostic tests.

02 Sep '21

LumiraDx Announces US Launch of its Rapid Onsite COVID-19 Surveillance Test

Works with easy-to-use portable instrument; allows pooling of 5 samples at one time; digital results in less than 12 minutes from sample application; $4 per sample London, UK (September 2, 2021) Today, LumiraDx, a next-generation point of care diagnostics testing company, announced the US launch of

20 Aug '21

LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics

Revised transaction terms adjust LumiraDx’s pro forma valuation for the combined group from $5 billion to $3 billion (excluding $115 million raised by CA Healthcare Acquisition Corp (“CAHC”) in its initial public offering). Terms establish a more attractive entry point for investors, and a highly

18 Aug '21

PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate

A new living systematic review and meta-analysis of SARS-CoV-2 antigen tests , currently including 133 clinical and analytical accuracy studies across 61 Antigen tests was just completed by Lukas Brümmer, Stephan Katzenschlager and Claudia Denkinger, all with Heidelberg University Hospital, along

05 Aug '21

LumiraDx Receives FDA Emergency Use Authorization for its COVID-19 Antibody Test, Now Allowing COVID-19 Antigen and Antibody Testing on a Single Point of Care Platform

LumiraDx SARS-CoV-2 Ab Test utilizes a combination RBD and S1 spike SARS CoV-2 antigen for the detection of total antibody (Ab) elicited in response to SARS-CoV-2 infection Test can be run with fingerstick blood in CLIA Waived point of care settings, such as physician office and pharmacy, and

09 Jul '21

LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test

Data Supports Use of LumiraDx SARS-CoV-2 Ag Test with Asymptomatic Patients* and LumiraDx SARS-CoV-2 Antibody Test Achieving WHO Requirements** for Diagnostic Performance London, UK – July 9, 2021 – LumiraDx today presented data supporting the use of its SARS-CoV-2 Ag Test for asymptomatic adults

30 Jun '21

LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete

As part of LumiraDx’s Fast Lab Solutions, the test enables laboratories to increase throughput of their existing open channel PCR systems to more than 250 tests per hour London, UK- June 30, 2021 – LumiraDx announced today that it has achieved CE Marking for LumiraDx RNA STAR Complete SARS-CoV-2.

24 Jun '21

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Company shares details of evaluation program to monitor SARS-CoV-2 variants as they emerge London, UK (June 24, 2021): Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company (“LumiraDx” or “Company”), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global

16 Apr '21

Shionogi Announces Agreement of Joint Sales with LumiraDx Japan Co., Ltd. for Novel Coronavirus Antigen test agent “LumiraDx SARS-CoV-2 Ag Test Strip” and diagnostic instrument in Japan

OSAKA, Japan, April, 16, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. ; hereafter “Shionogi”) is pleased to announce that it has concluded a joint sales contract with LumiraDx Japan Co., Ltd. (Head Office: Tokyo, Japan; President and CEO: Keisuke

Pagination

Current page 1
Page 2
Next page
Last page